title: Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
abstract: OBJECTIVE
  To assess the value of nuclear matrix protein-22 (NMP22), compared with urinary cytology, in predicting the recurrence of bladder cancer that is not transitional cell carcinoma (non-TCC).
  
  
  METHODS
  We tested the sensitivity, specificity and the predictive accuracy of NMP22 in the context of non-TCC bladder cancer recurrence, and compared it to the performance of urinary cytology. The study group comprised 2687 patients with history of non-muscle-invasive bladder cancer from 10 centres across four continents.
  
  
  RESULTS
  The mean patient age was 64.8 years and 75.4% were men; of all patients, 513 (19.1%) had positive urinary cytology, 906 (33.7%) had a positive NMP22 test (>or=10 units/mL) and 80 (3.0%) had non-TCC recurrence. Most of these, i.e. 60 (75%), were stage >or=T2. The sensitivity and specificity of urinary cytology were, respectively, 20.0% and 94.8%, vs 77.5% and 81.8% for NMP22 of >or=10 units/mL. The predictive accuracy of urinary cytology was 57.5%, vs 87.1% for NMP22 >or= 10 units/mL. A combined model that included dichotomized NMP22 and urinary cytology was 85.3% accurate.
  
  
  CONCLUSIONS
  The ability of a NMP22 level of >or=10 units/mL to predict non-TCC recurrence was better than that of urinary cytology, suggesting that NMP22 might have a role in the surveillance of patients at risk of non-TCC recurrence.
authors.affiliation: Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada.
authors.forename: Georg C
authors.initials: GC
authors.lastname: Hutterer
authors.forename: Pierre I
authors.initials: PI
authors.lastname: Karakiewicz
authors.forename: Craig
authors.initials: C
authors.lastname: Zippe
authors.forename: Gerson
authors.initials: G
authors.lastname: Lüdecke
authors.forename: Hans
authors.initials: H
authors.lastname: Boman
authors.forename: Marta
authors.initials: M
authors.lastname: Sanchez-Carbayo
authors.forename: Roberto
authors.initials: R
authors.lastname: Casella
authors.forename: Christine
authors.initials: C
authors.lastname: Mian
authors.forename: Martin G
authors.initials: MG
authors.lastname: Friedrich
authors.forename: Sanaa
authors.initials: S
authors.lastname: Eissa
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Akaza
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Serretta
authors.forename: Hans
authors.initials: H
authors.lastname: Hedelin
authors.forename: Raina
authors.initials: R
authors.lastname: Rupesh
authors.forename: Naoto
authors.initials: N
authors.lastname: Miyanaga
authors.forename: Arthur I
authors.initials: AI
authors.lastname: Sagalowsky
authors.forename: Paul
authors.initials: P
authors.lastname: Perrotte
authors.forename: Yair
authors.initials: Y
authors.lastname: Lotan
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Marberger
authors.forename: Shahrokh F
authors.initials: SF
authors.lastname: Shariat
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000473:pathology* / Q000652:urine; D002648:Child; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000652:urine; D009687:Nuclear Proteins / Q000378:metabolism*; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D012680:Sensitivity and Specificity; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000652:urine
chemical_list: D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; C100379:nuclear matrix protein 22